German drug maker Merck ups forecast for 2013

November 14, 2013

German chemicals and pharmaceuticals giant Merck KGaA said Thursday it is raising its full-year operating profit forecast thanks to improving sales and positive cost-cutting effects.

"Based on business performance in the third quarter of 2013, Merck is raising its for (operating profit) for the full year, despite negative currency effects," the company said in a statement.

Full-year earnings before interest, tax, depreciation and amortisation (EBITDA) were now projected to come out at 3.2-3.25 billion euros ($4.3-4.4 billion).

Previously, Merck had been pencilling in EBITDA of 3.1-3.2 billion euros for the whole of 2013.

"In addition to moderate organic sales growth, the main reason for this is the accelerated implementation of savings measures," Merck said.

In the three months to September, EBITDA climbed by 10.1 percent to 830.7 million euros.

Net profit rose to 340 million euros from 185 million euros a year earlier, but sales declined by 3.1 percent to 2.752 billion euros, hit by the strong euro.

spm/yad

Explore further: Higher prices for MS drug help drug firm Merck

Related Stories

Higher prices for MS drug help drug firm Merck

May 14, 2013

(AP)—Higher prices for its multiple sclerosis drug Rebif helped German pharmaceutical and high-tech materials company Merck KGaA post a 54 percent rise in first-quarter profit.

Merck back to profits on lower one-time costs

August 6, 2013

German drug and high-tech materials company Merck KGaA bounced back from losses this time last year to record a net profit of 316 million euros ($420 million) in the second quarter.

Bayer says new products push profits higher in Q3

October 31, 2013

German chemicals and pharmaceuticals group Bayer, maker of Aspirin, said on Thursday that new pharmaceutical products and favourable agrochemical prices gave profits a fillip in the third quarter.

Recommended for you

Sustaining biomedical research: Med school deans speak out

May 27, 2015

Cuts in federal support and unreliable funding streams are creating a hostile work environment for scientists, jeopardizing the future of research efforts and ultimately clinical medicine, according to leaders of the nation's ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.